TY - JOUR
T1 - Serum and imaging biomarkers
AU - Korenromp, Ingrid H.E.
AU - Maier, Lisa A.
AU - Grutters, Jan C.
N1 - Publisher Copyright:
© ERS 2022.
PY - 2022
Y1 - 2022
N2 - Over the last 10 years, a range of biomarkers have been evaluated in sarcoidosis. Based on extensive literature reviews over this period, the single serum analytes serum ACE, soluble IL-2 receptor and chitotriosidase stand out as potential diagnostic and monitoring tools with significant sensitivity and specificity, although none functions alone as a gold standard biomarker. Other proteins, such as YKL-40, Krebs von den Lungen-6, cathepsin S and IFN-γ-induced protein 10, show potential as biomarkers. Unfortunately, data on serum biomarkers for use as a prognostic tool (to predict disease outcome, irrespective of treatment) or as a predictive tool (to predict the effect of therapy) are scarce. With respect to imaging modalities as biomarkers,18F-FDG PET seems to have potential as a prognostic tool. This nuclear biomarker may also help in determining treatable inflammatory lesions in symptomatic patients with indecisive conventional tests. Future research on biomarkers, including those emerging from novel technologies, as well as the utility of combined biomarkers, should rely on carefully designed prospective trials to allow translation and implementation in routine clinical care.
AB - Over the last 10 years, a range of biomarkers have been evaluated in sarcoidosis. Based on extensive literature reviews over this period, the single serum analytes serum ACE, soluble IL-2 receptor and chitotriosidase stand out as potential diagnostic and monitoring tools with significant sensitivity and specificity, although none functions alone as a gold standard biomarker. Other proteins, such as YKL-40, Krebs von den Lungen-6, cathepsin S and IFN-γ-induced protein 10, show potential as biomarkers. Unfortunately, data on serum biomarkers for use as a prognostic tool (to predict disease outcome, irrespective of treatment) or as a predictive tool (to predict the effect of therapy) are scarce. With respect to imaging modalities as biomarkers,18F-FDG PET seems to have potential as a prognostic tool. This nuclear biomarker may also help in determining treatable inflammatory lesions in symptomatic patients with indecisive conventional tests. Future research on biomarkers, including those emerging from novel technologies, as well as the utility of combined biomarkers, should rely on carefully designed prospective trials to allow translation and implementation in routine clinical care.
UR - http://www.scopus.com/inward/record.url?scp=85153705892&partnerID=8YFLogxK
U2 - 10.1183/2312508X.10031720
DO - 10.1183/2312508X.10031720
M3 - Article
AN - SCOPUS:85153705892
SN - 2312-508X
VL - 2022
SP - 107
EP - 121
JO - ERS Monograph
JF - ERS Monograph
IS - 96
ER -